LABORIE completed its agreement with UroMed Technology, Inc. to acquire their Pelvic Muscle Rehabilitation business. UroMed Technology, Inc. develops, manufactures and distributes innovative and advanced biofeedback and electrical stimulation equipment, accessories and consumables for pelvic floor dysfunction in the treatment of Urinary and Fecal Incontinence.
“This acquisition strengthens our foundation in Pelvic Muscle Rehabilitation and expands our presence in the conservative therapy sector by offering brands that are synonymous with innovation and quality”, stated Brian Ellacott, President and CEO. “Both LABORIE and UroMed Technology, Inc. have a shared commitment to helping healthcare professionals deliver better products and services, and to make life more rewarding and dignified for those who use our products. By combining existing product lines with our extensive customer base, we can provide greater support and commitment to customers worldwide.”
LABORIE (www.laborie.com), headquartered in Toronto, Canada, is a leading global developer, manufacturer and marketer of innovative medical technology and consumables used for the diagnosis and treatment of Urinary and Fecal Incontinence, as well as other pelvic floor disorders in the Urology, Gynecology, and Colorectal fields.
Laborie Medical Technologies Inc. (LABORIE), a leading diagnostic and therapeutic medical technology company, today announced the first Optilume® procedures were performed in the UK at NHS Trust on June 11, 2021 by Dr. Pareeta Patel and Professor. Nick Watkin.
Laborie Medical Technologies Inc. (LABORIE), a leading diagnostic and therapeutic medical technology company, today announced the first Optilume® procedures were performed in Mannheim, Germany on January 22, 2021 by Dr. Georgi Tosev (Mannheim Urology).
Transaction demonstrates LABORIE’s commitment to providing innovative solutions to urologists globally LABORIE to invest $15 million in Urotronic Series C financing LABORIE secures option to acquire Urotronic’s Optilume™ technology